Ashley E. Ross, MD, PhD

This episode reviews treatment intensification in metastatic castration-sensitive prostate cancer, focusing on why ADT plus an ARPI is the current backbone of care, what barriers still limit its use, and how clinicians think about triplet therapy, de-intensification, frail patients, and emerging biomarker-driven options such as PARP inhibitors.

This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.

The faculty discusses how ARPI monotherapy may fit into the management of high-risk biochemically recurrent prostate cancer, with a focus on patient selection, trade-offs of monotherapy versus combination therapy, and practical counseling around efficacy, quality of life, and adverse events. The conversation also explores emerging questions around biomarkers, PARP inhibitors, treatment intensification, and how monotherapy may evolve as a therapeutic option in select patients.

The faculty discuss how androgen receptor pathway inhibitor–based strategies are reshaping the management of high-risk biochemical recurrence, with an emphasis on risk stratification, imaging, and patient selection for systemic therapy. The conversation also explores how long-term clinical evidence, treatment suspension, and emerging study designs are informing more individualized treatment decisions in practice.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.

The faculty discusses how ARPI monotherapy may fit into the management of high-risk biochemically recurrent prostate cancer, with a focus on patient selection, trade-offs of monotherapy versus combination therapy, and practical counseling around efficacy, quality of life, and adverse events. The conversation also explores emerging questions around biomarkers, PARP inhibitors, treatment intensification, and how monotherapy may evolve as a therapeutic option in select patients.

The faculty discuss how androgen receptor pathway inhibitor–based strategies are reshaping the management of high-risk biochemical recurrence, with an emphasis on risk stratification, imaging, and patient selection for systemic therapy. The conversation also explores how long-term clinical evidence, treatment suspension, and emerging study designs are informing more individualized treatment decisions in practice.

Panelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.

Drs Albala, Andriole, Ross, and Ulaner sum up recent advances and remaining unmet needs in the field of prostate cancer imaging and share hopes for the future.

Thought leaders discuss the possibility of using artificial intelligence to help interpret PSMA-PET results.

Panelists discuss how they typically document prostate cancer patient eligibility when ordering PSMA-PET imaging, and share strategies to optimize insurance coverage and reimbursement.

Gary Ulaner, MD, PhD, FACNM provides practical advice for radiologists who are generating PSMA-PET imaging reports, as well as for the urologists who are interpreting PSMA-PET results.

Shared insight from the panel on how they typically select radiotracers when ordering PSMA-PET scans in their clinical practice.

Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.

Urologist Ashley Ross, MD, PhD leads a discussion of the benefits and limitations of PSMA-PET in patients with prostate cancer, as compared to older imaging modalities.

Radiologist Gary Ulaner, MD, PhD, FACNM provides a comprehensive discussion on the FDA-approved PSMA radiotracer options that are available for use as part of PSMA-PET imaging.

Panelists consider how they have incorporated some newer imaging modalities, including PSMA-PET, into their clinical practice, and discuss the terminology that urologists and radiologists have recently used to describe these modalities.

A focused discussion on prostate-specific membrane antigen (PSMA) as a target for imaging and treatment for patients with prostate cancer.

Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.

Learning curve for technique is short, but capital expenditures are required.

Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.

Experts in prostate cancer review the role of PSMA PET imaging in advanced prostate cancer and its impact on disease management.

Bobby Liaw, MD, and Vivek K. Narayan, MD, MS, share clinical pearls for the management of adverse events from ARI-directed therapy in advanced prostate cancer.

Ashley E. Ross, MD, PhD, comments on the clinical significance of PSA response in patients with nmCRPC.

Vivek K. Narayan, MD, MS, reviews data from the SPARTAN trial in nmCRPC and discusses the importance of assessing health-related quality of life.

Ashley E. Ross, MD, PhD, discusses challenges and unmet needs in managing nmCRPC and Bobby Liaw, MD, reviews the PROSPER and ARAMIS trials.

Vivek K. Narayan, MD, MS, shares thoughts on approaching treatment selection of mCSPC and Ashley E. Ross, MD, PhD, comments on the use of relugolix in patients.